Abstract
The roles of different integrin alpha/beta (ITGA/ITGB) subunits in skin cutaneous melanoma (SKCM) and their underlying mechanisms of action remain unclear. Oncomine, UALCAN, GEPIA, STRING, GeneMANIA, cBioPortal, TIMER, TRRUST, and Webgestalt analysis tools were used. The expression levels of ITGA3, ITGA4, ITGA6, ITGA10, ITGB1, ITGB2, ITGB3, ITGB4, and ITGB7 were significantly increased in SKCM tissues. The expression levels of ITGA1, ITGA4, ITGA5, ITGA8, ITGA9, ITGA10, ITGB1, ITGB2, ITGB3, ITGB5, ITGB6 and ITGB7 were closely associated with SKCM metastasis. The expression levels of ITGA1, ITGA4, ITGB1, ITGB2, ITGB6, and ITGB7 were closely associated with the pathological stage of SKCM. The expression levels of ITGA6 and ITGB7 were closely associated with disease-free survival time in SKCM, and the expression levels of ITGA6, ITGA10, ITGB2, ITGB3, ITGB6, ITGB7, and ITGB8 were markedly associated with overall survival in SKCM. We also found significant correlations between the expression of integrin subunits and the infiltration of six types of immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells). Finally, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed, and protein-protein interaction (PPI) networks were constructed. We have identified abnormally-expressed genes and gene regulatory networks associated with SKCM, improving understanding of the underlying pathogenesis of SKCM.
Introduction
Skin cutaneous melanoma (SKCM) is among the most aggressive and lethal forms of skin cancer, characterized by a high potential for metastasis and a complex tumor microenvironment (TME). Integrins are a family of heterodimeric cell-surface receptors, composed of alpha and beta subunits, that facilitate cell-extracellular matrix (ECM) adhesion and signal transduction. While their general role in cancer is recognized, the specific contributions of individual integrin subunits to melanoma progression, patient survival, and immune cell interaction have remained fragmented. This study systematically maps the integrin landscape in SKCM to identify novel therapeutic targets and prognostic biomarkers.
Methods
The researchers employed a robust bioinformatic pipeline to analyze large-scale genomic and clinical datasets, primarily sourced from The Cancer Genome Atlas (TCGA) and GTEx.
- Expression & Staging Analysis: Tools such as Oncomine, UALCAN, and GEPIA were used to compare integrin expression levels between normal skin, primary tumors, and metastatic tissues.
- Survival Correlation: GEPIA was utilized to determine the impact of specific gene expression on overall survival (OS) and disease-free survival (DFS).
- Immune Profiling: The TIMER database was used to correlate integrin expression with the infiltration of six major immune cell types, including CD8+ T cells and macrophages.
- Functional Enrichment: Webgestalt, STRING, and GeneMANIA were used for Gene Ontology (GO), KEGG pathway analysis, and the construction of protein-protein interaction (PPI) networks to identify regulatory hubs.
Results
Differential Expression and Metastasis
The study identified a significant upregulation of ITGA3, ITGA4, ITGA6, ITGA10, and ITGB1, ITGB2, ITGB3, ITGB4, and ITGB7 in SKCM tissues compared to normal skin. A broad "metastasis signature" was observed, with nearly the entire integrin family (including ITGA1, 4, 5, 8, 9, 10 and ITGB1, 2, 3, 5, 6, 7) showing strong associations with metastatic progression.
Prognostic Biomarkers and Immune Infiltration
While many subunits were upregulated, specific genes emerged as critical prognostic indicators. ITGA6 and ITGB7 were uniquely linked to disease-free survival, while a larger group (ITGA6, ITGA10, ITGB2, ITGB3, ITGB6, ITGB7, and ITGB8) was associated with overall survival.
Furthermore, a significant positive correlation was found between integrin expression and immune cell infiltration. For instance, ITGA4 and ITGB2 levels were closely tied to the presence of CD8+ T cells and neutrophils, suggesting these integrins may modulate the immune landscape of the tumor microenvironment.
Discussion and Conclusion
This study highlights ITGA4, ITGB2, and ITGB7 as the most promising therapeutic targets and biomarkers in SKCM. These subunits appear to drive metastasis and influence immune infiltration, marking them as high-priority candidates for future clinical research.
However, it is important to note that these findings are based entirely on in silico bioinformatic analysis. While the data from multiple high-quality databases is consistent, experimental validation through in vitro and in vivo studies is necessary to confirm the functional roles of these integrins and their potential for clinical translation. Future work should focus on the development of targeted therapies, such as monoclonal antibodies, and assessing their safety and efficacy in melanoma patients.
Summary updated